Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Marco Valgimigli MD

Marco Valgimigli MD

Deputy Chief of Cardiology and Director of the Cardiovascular Research Service, Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland

Prof. Marco Valgimigli is Deputy Chief of Cardiology and Director of the Cardiovascular Research Service at Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland. He designed and conducted more than 20 investigator-initiated multicenter randomized clinical trials and served as steering or executive committee member of numerous sponsor-driven interventional studies. During the last few years, he has been task force member of multiple European Society of Cardiology (ESC) guidelines and chaired the 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) and the upcoming 2022 EAPCI/ACVC/EAPC consensus document on antithrombotic treatment strategies in patients with established coronary artery disease.

Disclosures

M.V. reports grants and/or personal fees from Astra Zeneca, Terumo, Alvimedica/CID, Abbott Vascular, Daiichi Sankyo, Bayer, CoreFLOW, Idorsia Pharmaceuticals-Ltd, Universität Basel Department Klinische Forschung, Vifor, Bristol-Myers-Squib SA, Biotronik, Boston scientific, Medtronic, Vesalio, Novartis, Chiesi, PhaseBio, outside the submitted work.

The other authors report no relationships relevant to the contents of this paper to disclose.

Recent Contributions to PracticeUpdate:

  1. Efficacy and Safety of Antithrombotic Strategies Within and Beyond 12 Months in Patients With Established CAD

Most Read This Week

Recently Updated